Jubilant Pharmova Dirección

Dirección controles de criterios 1/4

El CEO de Jubilant Pharmova's es Priyavrat Bhartia, nombrado en Jun 2023, tiene una permanencia de menos de un año. posee directamente un 0.88% de las acciones de la empresa, con un valor de ₹945.97M. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 6.9 años, respectivamente.

Información clave

Priyavrat Bhartia

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	0.9%
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	7yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Priyavrat Bhartia (47 yo)

less than a year

Permanencia

Mr. Priyavrat Bhartia, MBA, is the Non-Executive Chairman at Digicontent Limited and has been its Non-Executive Director since August 14, 2017. He has been Non-Executive Director of Hindustan Media Venture...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Arvind Chokhany	Group CFO & Whole-Time Director	less than a year	₹53.43m	sin datos
Laxshmivarahan Ramasubramani	Group Chief Digital & Information Officer	no data	₹16.53m	sin datos
Naresh Kapoor	Company Secretary & Compliance Officer	1.8yrs	₹6.86m	sin datos
Praveen Gupta	Executive VP & Head of Direct Taxation	no data	₹21.06m	sin datos
K.V.S Kumar	Chief Sustainability Officer	no data	₹16.73m	sin datos
Priyavrat Bhartia	MD & Director	less than a year	sin datos	0.88% ₹ 959.5m
Arjun Bhartia	Joint MD & Director	less than a year	sin datos	sin datos
Prakash Bisht	Executive VP of Group Accounts	no data	sin datos	sin datos
Surajit Pal	Head of Investor Relations	no data	sin datos	sin datos
Sanjay Gupta	Executive VP & Head of Legal	9.5yrs	₹3.34m	sin datos
Shantanu Jha	Group Chief Human Resources Officer	1.3yrs	sin datos	sin datos
Rajagopal Sankaraiah	Advisor	4.2yrs	₹67.29m	sin datos

1.3yrs

Permanencia media

49yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 530019 no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Arvind Chokhany	Group CFO & Whole-Time Director	3.1yrs	₹53.43m	sin datos
Priyavrat Bhartia	MD & Director	7yrs	sin datos	0.88% ₹ 959.5m
Arjun Bhartia	Joint MD & Director	7yrs	sin datos	sin datos
Jinang Parekh	Whole-Time Director	1.3yrs	sin datos	sin datos
Shyam Sunder Bhartia	Chairman	45.9yrs	sin datos	0.084% ₹ 92.1m
Sushil Roongta	Independent Non-Executive Director	7yrs	₹1.76m	sin datos
Arun Seth	Independent Non-Executive Director	5.6yrs	₹1.38m	0.0013% ₹ 1.4m
Hari Bhartia	Co-Chairman	40.5yrs	₹119.90m	0.23% ₹ 254.8m
Vivek Mehra	Independent Non-Executive Director	7yrs	₹1.85m	sin datos
Shirish Belapure	Additional Independent Non-Executive Director	1.2yrs	sin datos	sin datos

7.0yrs

Permanencia media

66.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 530019 se considera experimentada (6.9 años de antigüedad promedio).

Jubilant Pharmova Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Jubilant Pharmova Limited Announces the Resignation of Kumar Ramamurthi as Director and Whole-Time Director, Effective October 31, 2023

Jubilant Pharmova Limited, Annual General Meeting, Aug 31, 2023

Jubilant Pharmova Limited Announces Change in Directorate

Jubilant Pharmova Limited Appoints Jaidev Rajpal as Head of Its Generics Business, Effective October 11, 2022

Jubilant Pharmova Limited, Annual General Meeting, Sep 26, 2022

High number of new directors

Recent updates

Third quarter 2024 earnings released: EPS: ₹4.22 (vs ₹0.98 loss in 3Q 2023)

Jubilant Pharmova Limited Announces the Resignation of Kumar Ramamurthi as Director and Whole-Time Director, Effective October 31, 2023

Second quarter 2024 earnings released: EPS: ₹3.94 (vs ₹0.34 in 2Q 2023)

Price target decreased by 8.9% to ₹395

Jubilant Pharmova Limited to Report Fiscal Year 2024 Results on May 17, 2024

Jubilant Pharmova Limited, Annual General Meeting, Aug 31, 2023

First quarter 2024 earnings released: EPS: ₹0.40 (vs ₹2.96 in 1Q 2023)

Jubilant Pharmova Limited to Report Fiscal Year 2023 Results on Jul 19, 2023

Jubilant Pharmova Limited Announces Change in Directorate

Full year 2023 earnings released: ₹3.83 loss per share (vs ₹26.01 profit in FY 2022)

Jubilant Pharmova Limited to Report Q4, 2023 Results on May 29, 2023

Now 21% undervalued after recent price drop

Price target decreased by 11% to ₹384

Third quarter 2023 earnings released: ₹0.98 loss per share (vs ₹3.20 profit in 3Q 2022)

Jubilant Pharmova Limited to Report Q3, 2023 Results on Feb 03, 2023

Price target decreased to ₹391

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Jubilant Pharmova Limited to Report Q2, 2023 Results on Oct 21, 2022

Jubilant Pharmova Limited Appoints Jaidev Rajpal as Head of Its Generics Business, Effective October 11, 2022

Price target decreased to ₹434

Jubilant Pharmova Limited Recommends Dividend for the Year Ended March 31, 2022, Payable on or Before October 24, 2022

Jubilant Pharmova Limited, Annual General Meeting, Sep 26, 2022

Consensus forecasts updated

Upcoming dividend of ₹5.00 per share

First quarter 2023 earnings released: EPS: ₹2.96 (vs ₹10.09 in 1Q 2022)

Jubilant Pharmova Limited Recommends Final Dividend for the Year Ended March 31, 2022, Payable on or Before October 26, 2022

Jubilant Pharmova Limited Recommends Final Dividend for the Year Ended March 31, 2022, Payable on or Before October 26, 2022

Jubilant Pharmova Limited to Report Q1, 2023 Results on Aug 02, 2022

High number of new directors

Price target decreased to ₹507

Jubilant Pharmova Limited Approves Executive and Board Changes

Consensus EPS estimates fall by 18%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Jubilant Pharmova Limited Recommends Dividend for the Year Ended March 31, 2022, Payable on or Before September 7, 2022

Now 21% undervalued after recent price drop

Investor sentiment improved over the past week

Consensus revenue estimates fall by 11%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to ₹711

Second quarter 2022 earnings released: EPS ₹8.97 (vs ₹14.06 in 2Q 2021)

Price target decreased to ₹802

Price target decreased to ₹869

First quarter 2022 earnings released: EPS ₹10.09 (vs ₹5.53 in 1Q 2021)

Jubilant Pharmova Announces That the US FDA Has Placed Roorkee Facility Under Import Alert

Consensus revenue estimates fall to ₹65.7b

Full year 2021 earnings released: EPS ₹36.05 (vs ₹56.40 in FY 2020)

New 90-day low: ₹752

Price target raised to ₹1,021

Analysts update estimates

President of Manufacturing & Whole-Time Director Anant Pande has left the company

CEO of Life Science Ingredients & Whole-Time Director Rajesh Srivastava has left the company

Jubilant Pharmova Limited Announces Directorate Changes

Third quarter 2021 earnings released: EPS ₹13.75 (vs ₹12.77 in 3Q 2020)

Earnings beat expectations, revenue disappoints

New 90-day high: ₹1,026

Jubilant Life Sciences Limited to Report Q3, 2021 Results on Feb 05, 2021

New 90-day high: ₹978

New 90-day high: ₹866

Market bids up stock over the past week

New 90-day high: ₹820

New 90-day low: ₹683

Revenue and earnings miss expectations

Second quarter 2021 earnings released: EPS ₹14.06

Jubilant Life Sciences Limited to Report Q2, 2021 Results on Nov 04, 2020

Independent Non-Executive Director recently bought ₹1.1m worth of stock

Analysts lower EPS estimates to ₹55.56

Price target raised to ₹725

First quarter earnings released

Full year earnings released - EPS ₹56.39